France Next Generation Sequencing Market Size, Growth, Share & Trends Analysis
France Next Generation Sequencing Market by Product (Reagents, Kits, Platforms), Service (CHIP Sequencing, Whole Genome, Methyl, RNA Sequencing), Technology (SBS, Nanopore) Workflow (Sequencing, Data Analysis), Application, Competition - Forecast to 2031
OVERVIEW
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
The France Next Generation Sequencing market, valued at USD 0.54 billion in 2025, stood at USD 0.59 billion in 2026 and is projected to advance at a resilient CAGR of 14.2% from 2026 to 2031, culminating in a forecasted valuation of USD 1.14 billion by the end of the period. Next-generation sequencing refers to non-Sanger-based, high-throughput DNA sequencing technologies. NGS is fundamentally based on sequencing by synthesis (SBS), ion semiconductor sequencing, single-molecule real-time (SMRT) sequencing, and nanopore sequencing. These technologies are designed to process large volumes of genomic data and can be used in various applications, such as clinical diagnostics, drug discovery & development, and agricultural research.
KEY TAKEAWAYS
-
BY OFFERINGBy offering, the services segment is projected to register the highest CAGR of 18.5% during the forecast period.
-
BY CONSUMABLE TYPEBy consumable type, sequencing kits & reagents are projected to register a CAGR of 13.0% during the forecast period.
-
BY SERVICE TYPEBy service type, sequencing services is expected to register the highest CAGR of 18.7%.
-
COMPETITIVE LANDSCAPEIllumina, Thermo Fisher Scientific, and Agilent Technologies were identified as leading players in the France next-generation sequencing market, given their strong market presence and comprehensive product portfolios.
The next-generation Sequencing market in France is projected to register a growth rate of 14.2% during the forecast period, driven by substantial government investments in genomics research and infrastructure development. The market is rapidly expanding, fueled by the launch of the France Genomic Medicine Initiative in 2025 and the establishment of genome sequencing centers throughout the country. In 2022, the government invested around USD 740 million to set up 12 genome sequencing centers by 2025. The introduction of high-throughput sequencing platforms, along with an increasing emphasis on personalized medicine and precision diagnostics, is driving the demand for advanced genomics technologies across France.
TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS
The France next-generation sequencing market is currently experiencing a phase of innovation and rapid adoption. Healthcare systems and research institutions in France are witnessing advancements in sequencing platform development and regulatory frameworks. This progress aligns with emerging trends in precision medicine, oncology diagnostics, and rare disease identification. In France, the use of high-throughput sequencing platforms, advanced bioinformatics tools, and integrated data management systems is increasing among hospitals, diagnostic laboratories, and research centers. These technologies facilitate faster turnaround times for genetic testing, enable comprehensive genomic profiling, and support the development of targeted therapies aligned with personalized medicine approaches. Government bodies and regulatory authorities are encouraging the development of local sequencing infrastructure, the adoption of standardized protocols, and public-private research collaborations. These initiatives help accelerate clinical implementation and promote the adoption of validated, clinically relevant sequencing applications tailored to the needs of the French patient population.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
MARKET DYNAMICS
Level
-
Technological advancements in sequencing platforms
-
Rising demand for precision medicine and personalized healthcare
Level
-
High capital investment and operational costs
Level
-
Expanding applications in clinical diagnostics
Level
-
Data management and storage complexity
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
Driver: Technological advancements in sequencing platforms
Continuous advancements in sequencing technologies are significantly contributing to the growth of the France next-generation sequencing (NGS) market. Innovations in sequencing platforms have led to improvements in throughput, accuracy, and turnaround time, enabling laboratories to process larger volumes of genomic data with greater efficiency.
Restraint: High capital investment and operational costs
Despite the gradual decline in sequencing costs over the past decade, the implementation of next-generation sequencing (NGS) technologies continues to require substantial capital investment. Establishing a fully functional NGS laboratory involves significant expenditure on advanced sequencing instruments, specialized reagents and consumables, high-performance computational infrastructure, and data storage systems.
Opportunity: Expanding applications in clinical diagnostics
The expanding utilization of next-generation sequencing (NGS) in clinical diagnostics presents a significant growth opportunity for the France next-generation sequencing market. NGS technologies are increasingly being adopted across various diagnostic areas, including oncology, infectious disease detection, prenatal screening, and rare genetic disorder identification. The ability of NGS to simultaneously analyze multiple genes with high accuracy enables clinicians to identify disease-associated mutations more efficiently than traditional diagnostic methods. This capability supports earlier diagnosis, improved disease characterization, and more personalized treatment strategies.
Challenge: Data management and storage complexity
Next-generation sequencing (NGS) technologies generate extremely large volumes of genomic data, creating significant challenges related to data management, storage, and analysis. Each sequencing run can produce terabytes of raw data that must be securely stored, processed, and interpreted using advanced computational tools and bioinformatics pipelines. Consequently, laboratories and research institutions must invest in high-performance computing infrastructure, cloud storage solutions, and specialized data management systems to efficiently handle these datasets.
FRANCE NEXT GENERATION SEQUENCING MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES
| COMPANY | USE CASE DESCRIPTION | BENEFITS |
|---|---|---|
 |
Partnership with the Jean Perrin Center at Clermont-Ferrand University Hospital, along with Toulouse Oncopole and Bordeaux University Hospital, to evaluate comprehensive genomic profiling (CGP) for patients with advanced cancers using the TruSight Oncology 500 assay. | Enables precision oncology by identifying tumor biomarkers and guiding targeted therapy selection | Supports broader adoption of NGS-based genomic profiling in the French healthcare system |
 |
Collaboration with Institut Curie to develop and commercialize the “SureSelect CD Curie CGP” kit, an NGS-based comprehensive genomic profiling solution designed to identify genetic abnormalities in solid tumors. | Enables detailed tumor genomic profiling in a single test, improving cancer diagnosis and helping clinicians tailor targeted treatment strategies for patients |
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET ECOSYSTEM
The France next-generation sequencing market is a collaborative ecosystem where sequencing platform manufacturers, consumables suppliers, service providers, bioinformatics companies, research institutions, and healthcare professionals work together to develop and implement genomic technologies in clinical and research settings. Companies supply a variety of sequencing platforms, consumables (including kits & reagents), and services encompassing sequencing and data analysis. Academic & research institutes, hospitals, and specialized genomic centers support the development and validation of sequencing protocols and applications. Healthcare institutions and diagnostic laboratories utilize the sequencing technologies, benefiting from supportive government initiatives and evolving reimbursement frameworks that facilitate the integration of genomic medicine into routine clinical practice.
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET SEGMENTS
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
France Next-generation Sequencing Market, by Application
The market spans multiple application areas, including diagnostics, drug discovery & development, agriculture & animal research, and other applications. The diagnostics segment represents a significant and growing area, driven by the increasing adoption of genomic testing for cancer profiling, rare disease identification, prenatal screening, and infectious disease detection.
France Next-generation Sequencing Market, by Offering
The market is divided into products and services. In 2025, the products segment held the largest share of the market, driven by repeat purchases and steady workflow demand.
REGION
France is a leading market for Next-generation sequencing within Europe.
France is positioned as a leading market for next-generation sequencing within Europe, driven by substantial government investments in genomic research infrastructure and the implementation of national genomic medicine initiatives. The establishment of dedicated genome sequencing centers, the launch of the France Genomic Medicine Initiative in 2025, and ongoing investments in proteomics and genomics research are facilitating rapid market growth. The country's strong research base, well-developed healthcare infrastructure, and commitment to integrating genomic technologies into clinical practice are supporting the transition of sequencing applications from research settings to routine clinical use.
FRANCE NEXT GENERATION SEQUENCING MARKET: COMPANY EVALUATION MATRIX
Illumina is recognized as a leading player in the France next-generation sequencing market, offering a broad portfolio of sequencing platforms, consumables, and bioinformatics solutions for research and clinical applications. The company maintains a strong presence in France through collaborations with research institutes, hospitals, and genomic laboratories. Another key player is Thermo Fisher Scientific, which strengthens its market position by providing advanced sequencing systems, integrated genomic workflows, and specialized reagents used in oncology, infectious disease research, and genetic disorder diagnostics.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
KEY MARKET PLAYERS
- Illumina, Inc. (US)
- Thermo Fisher Scientific (US)
- Agilent Technologies, Inc. (US)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- QIAGEN (Netherlands)
- Oxford Nanopore Technologies plc (UK)
- PacBio (US)
- Eurofins Scientific (Luxembourg)
MARKET SCOPE
| REPORT METRIC | DETAILS |
|---|---|
| Market Size in 2025 (Value) | USD 0.54 Billion |
| Market Forecast in 2031 (Value) | USD 1.14 Billion |
| Growth Rate | CAGR of 14.2% from 2026–2031 |
| Years Considered | 2024–2031 |
| Base Year | 2025 |
| Forecast Period | 2026–2031 |
| Units Considered | Value (USD Million) |
| Report Coverage | Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, and Trends |
| Segments Covered |
|
| Country Covered | France |
WHAT IS IN IT FOR YOU: FRANCE NEXT GENERATION SEQUENCING MARKET REPORT CONTENT GUIDE
DELIVERED CUSTOMIZATIONS
We have successfully delivered the following deep-dive customizations:
| CLIENT REQUEST | CUSTOMIZATION DELIVERED | VALUE ADDS |
|---|---|---|
| Understanding adoption patterns for next-generation sequencing technologies across French healthcare and research institutions | Assessed sequencing technology adoption trends across hospital laboratories, diagnostic centers, research institutions, and pharmaceutical companies in France, highlighting differences in platform preferences, application focus areas, and integration of bioinformatics capabilities. | Helps clients align product & service offerings with institutional needs, budget constraints, and application priorities across different customer segments. |
| Identifying local service providers and partnership opportunities | Mapped regional sequencing service providers, bioinformatics companies, contract research organizations, and academic collaborators across France, with insights into service capabilities, turnaround times, data analysis expertise, and collaborative research programs. | Supports partnership strategies, facilitates market entry, enables service network development, and improves access to specialized expertise and infrastructure. |
RECENT DEVELOPMENTS
- July 2023 : Agilent Technologies partnered with Institut Curie to launch the SureSelect CD Curie Comprehensive Genomic Profiling (CGP) assay, an advanced next-generation sequencing (NGS) solution designed for the molecular analysis of solid tumors. The assay enables the simultaneous sequencing of approximately 571 cancer-related genes, allowing clinicians and researchers to detect multiple genomic alterations associated with tumor development and progression.
Table of Contents
Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.
Methodology
This study on the France next Generation Sequencing Market employed secondary sources, directories, and databases to gather pertinent information. To gather and validate important qualitative and quantitative data and evaluate market growth prospects, in-depth interviews were conducted with many primary respondents including key industry participants, subject-matter experts (SMEs), C-level executives from key market players, and industry consultants. After estimating the France next Generation Sequencing Market using several research strategies, the size of the final market was obtained by triangulating data from primary research.
Secondary Research
The secondary sources referred to for this research study include publications from government sources. These include the Centers for Disease Control and Prevention (CDC), the US Food and Drug Administration (FDA), the World Health Organization (WHO), the American Cancer Society (ACS), the National Center for Biotechnology Information (NCBI), the National Institutes of Health (NIH), National Human Genome Research Institute (NHGRI), International Agency for Research on Cancer (IARC), National Institute for Infectious Diseases (IRCCS), Association for Clinical Genomic Science (ACGS), American Society of Human Genetics (ASHG), European Society of Human Genetics (ESHG), Asia Pacific Society of Human Genetics (APSHG), Nature Reviews Genetics, Nature Methods, Biotechnology and Biological Sciences Research Council (BBSRC), Organisation for Economic Co-operation and Development (OECD), Genome Research, National Cancer Institute (NCI), European Medicines Agency (EMA), Population Health Research Institute (PHRI), PubMed, World Bank, and the World Health Organization (WHO), among others. Secondary sources also included corporate & regulatory filings, such as annual reports, SEC filings, investor presentations, and financial statements; business magazines & research journals; press releases; and trade, business, and professional associations. Secondary data was collected and analyzed to arrive at the overall size of the global France next Generation Sequencing Market, which was validated through primary research.
Primary Research
Extensive primary research was conducted after acquiring basic knowledge about the global France next Generation Sequencing Market scenario through secondary research. Several primary interviews were conducted with market experts from the supply side, such as C-level and D-level executives, operational managers, marketing & sales managers of key manufacturers, distributors, and channel partners of companies providing NGS; experts from the demand side, such as personnel from academic & research institutes, hospitals, clinics and diagnostic labs, pharmaceutical & biopharmaceutical industries, CROs, and other end users. These interviews were conducted across six major regions, including North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa. Approximately 70% and 30% of the primary interviews were conducted with supply-side and demand-side participants, respectively. This primary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Both top-down and bottom-up approaches were used to estimate and validate the total size of the France next Generation Sequencing Market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
Data Triangulation
To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Market Definition
NGS refers to non-Sanger-based, high-throughput DNA sequencing technologies. DNA strands can be sequenced simultaneously, yielding substantially more throughput and minimizing the need for fragment-cloning methods often used in the Sanger sequencing of genomes. NGS is fundamentally based on sequencing by synthesis (SBS), ion semiconductor sequencing, single-molecule real-time (SMRT) sequencing, and nanopore sequencing.
Stakeholders
- NGS instrument manufacturers, vendors, and distributors
- NGS service providers
- NGS bioinformatics/data analysis companies
- Research laboratories and academic institutes
- Venture capitalists and other government funding organizations
- Research and consulting firms
- Healthcare institutions (hospitals and diagnostic clinics)
- Pharmaceutical and biotechnology companies
- Academic and government research institutes
- Life science companies
Report Objectives
- To define, describe, and forecast the France next Generation Sequencing Market based on offerings, product type, platform technology, product workflow, product end user, service type, service workflow, service end user, application, and region
- To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
- To strategically analyze micro markets with respect to individual growth trends, prospects, and contributions to the overall France next Generation Sequencing Market
- To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments with respect to six main regions, namely, North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
- To profile the key players in the global France next Generation Sequencing Market and comprehensively analyze their platforms, reagents, kits, consumables, and services portfolios, market positions, and core competencies
- To track and analyze competitive developments such as product & service launches, expansions, agreements, and collaborations in the France next Generation Sequencing Market
- To benchmark players within the France next Generation Sequencing Market using the ‘Company Evaluation Matrix' framework, which analyzes market players based on various parameters within the broad categories of business and service strategy.
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This ReportPersonalize This Research
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
Let Us Help You
- What are the Known and Unknown Adjacencies Impacting the France Next Generation Sequencing Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
Custom Market Research Services
We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements
Get 10% Free Customisation
Still Researching the
France Next Generation Sequencing Ecosystem?
See the competitors, opportunity evaluation, and growth signals shaping it - Instantly!
Generate 15+ consulting-grade strategic intelligence outputs - from competitor analysis to board-ready strategy decks, tailored to your France Next Generation Sequencing growth question.
Growth opportunities and latent adjacency in France Next Generation Sequencing Market